$3.670
+0.030 (+0.82%)Zum Schluss
OM-News
OM-Events
Company Reports Q1 Revenue of $27.86M, Below Expectations
Reports Q1 revenue $27.86M, consensus $28.9M. "We delivered a solid first quarter and continued to make meaningful progress on our path to profitability, driven by disciplined execution and another quarter of record gross margin performance," said Leslie Trigg, Chair and Chief Executive Officer. "With utilization strong and service margins expanding, we remain focused on driving broader adoption of Tablo across care settings and confident in our full-year outlook."
Outset Reiterates 2026 Revenue Guidance of $125M to $130M
The company said, "Outset reiterated its 2026 revenue guidance of $125 million to $130 million, a 5% to 9% increase over $119.5 million in 2025, and non-GAAP gross margin guidance in the low to mid-40% range for the year."
Outset Provides 2026 Revenue Guidance of $125M to $130M
The company said, "Outset provided 2026 revenue guidance of $125 million to $130 million, a 5% to 9% increase over $119.5 million in 2025, and non-GAAP gross margin guidance in the low to mid-40% range for the year."
Outset Medical Reports Q4 Revenue of $28.87M
Reports Q4 revenue $28.87M, consensus $28.9M. "We enter 2026 standing on a strong foundation for growth, well capitalized, and with a highly differentiated platform to help healthcare providers transform their clinical, operational and financial outcomes by insourcing dialysis with Outset," said Leslie Trigg, chair and CEO.
Outset Medical Receives FDA 510(k) Clearance
Outset Medical announced 510(k) clearance by the U.S. Food and Drug Administration of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability and connectivity for hospitals, health systems and home providers of dialysis.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.